Medtronic
Based in DC
🤖
AI Overview
With $260K in lobbying spend across 5 quarterly filings, Medtronic is an active lobbying client. Their lobbying covers 6 issue areas. Active from 2018 to 2019.
$260K
Total Spend
2
Years Active
1
Firms Hired
3
Lobbyists Deployed
6
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $220K |
| 2019 | $40K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Disaster Planning, Budget/Appropriations, Homeland Security, Health Issues, Taxation and 1 more
- •Issues related to the federal response to the hurricanes.
- •Monitored cyber security issues.
- •Issues related to opioids; issues related to stark law reform; issues related to natural disaster recovery efforts.
- •Monitor implementation of H.R. 1, The Tax Cut and Jobs Act, as it relates to corporate tax reform, the taxation of multinational companies and Puerto Rico. Issues related to the medical device tax.
Related Analysis
Related Investigations
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
American Clinical Laboratory Assn
$23.9M total spend
Siemens Medical Solutions USA, INC
$9.6M total spend
National Association of Benefits and Insurance Professionals
$8.6M total spend
Blood Cancer United (FKA the Leukemia & Lymphoma Society)
$6.8M total spend
Nemours Foundation - a Florida Not-for-profit Corporation
$6.3M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.